BIOCHEMICAL STUDIES AND CLONING OF DELTA SUBTYPES
Delta 亚型的生化研究和克隆
基本信息
- 批准号:6237962
- 负责人:
- 金额:$ 10.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-02-20 至 1998-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This proposal is part of a program project that seeks to produce and
characterize non-peptidic compounds acting at delta opioid receptors.
A basic hypothesis of this program project is that drugs acting on delta
opioid receptors will be potent analgesics, but will lack many of the
undesirable side effects of the opiate drugs now in use. Furthermore,
it is hypothesized that there are multiple delta opioid receptor subtypes
and that an additional increase in therapeutic specificity can be
achieved by drugs selective for particular delta receptor subtypes. Two
recent developments, the discovery of the non-peptidic compound BW373U86
and the cloning of mouse delta opioid receptors, provide a foundation for
the testing of these hypotheses and the work proposed here.
BW373U86 is the only known selective delta receptor agonist that is not
a peptide. The racemic mixture of BW373U86 was resolved into its two (+)
and (-) isomers by Dr. Kenner Rice who proposes to have each form labeled
with tritium for studies by radioligand binding. We propose to do this
characterization by tissue homogenate binding and receptor
autoradiography studies using mouse and rat neural tissue. Parallel
studies with radiolabeled forms of the established ligands [4'-Cl-
Phe4]DPDPE and naltrindole in addition to binding inhibition studies
designed to characterize the site(s) labeled by BW373U86 will be used to
define its properties at CNS receptors. This information will assist the
design of new analogs of BW373U86 and help to explain some of the unusual
pharmacological properties of this novel compound. Some of these
properties, including high potency at delta receptors in the mouse vas
deferens but low analgesic potency suggest that BW373U86 may be selective
for delta receptor subtypes.
We also intend to explore the hypothesis of delta opioid receptor
subtypes by cloning mouse and human cDNAs encoding the proposed subtypes.
Since at least one subtype of the mouse delta opioid receptor has been
cloned, we will use polymerase chain reaction methods to product
oligonucleotide probes selective for delta opioid receptors. These
probes will be used to initially screen mouse and subsequently human
brain cDNA libraries for the presence of multiple delta opioid receptors.
The identification of cDNAs for delta receptor subtypes is important
since selective radioligands are not available which impedes the
development of selective drugs for these subtypes. Furthermore, the only
way by which any human delta opioid receptors can be studied is through
the use of recombinant cells expressing these receptors. cDNAs for delta
receptors will be expressed in mammalian cells to produce cell lines
having defined delta receptor subtypes. The cell lines expressing
different human delta opioid receptor subtypes will be used for the
development of specific radioligand binding and functional assays for the
screening and characterization of the new compounds proposed elsewhere
by this program project proposal.
该提案是一个旨在生产和
表征作用于δ阿片受体的非肽化合物。
该项目的一个基本假设是,
阿片受体将是有效的镇痛剂,但将缺乏许多
现在使用的鸦片类药物的不良副作用。 此外,委员会认为,
假设存在多种δ阿片受体亚型,
并且治疗特异性的额外增加可以
通过对特定δ受体亚型有选择性的药物来实现。 两
最近的发展,非肽化合物BW 373 U86的发现
以及小鼠δ阿片受体的克隆,为
这些假设的测试和这里提出的工作。
BW 373 U86是唯一已知的选择性δ受体激动剂,
肽。 将BW 373 U86的外消旋混合物拆分成其两个(+)
和(-)异构体由肯纳赖斯博士谁建议有每一个形式标记
用氚进行放射性配体结合研究。 我们建议这样做
组织匀浆结合和受体表征
使用小鼠和大鼠神经组织的放射自显影研究。 平行
用已建立的配体[4 '-Cl-]的放射性标记形式进行的研究
Phe 4]DPDPE和纳曲吲哚以及结合抑制研究
设计用于表征BW 373 U86标记的部位,
定义其在CNS受体上的特性。 这些信息将有助于
BW 373 U86的新类似物的设计,并帮助解释一些不寻常的
这种新化合物的药理学性质。 其中一些
特性,包括对小鼠血管中δ受体的高效力
但镇痛效力较低,表明BW 373 U86可能具有选择性
δ受体亚型的基因。
我们还打算探讨δ阿片受体假说
通过克隆编码所提出的亚型的小鼠和人cDNA,
由于小鼠δ阿片受体的至少一种亚型已经被发现,
克隆,我们将使用聚合酶链反应方法,
对δ阿片受体具有选择性的寡核苷酸探针。 这些
探针将用于最初筛选小鼠,随后筛选人
脑cDNA文库中存在多种δ阿片受体。
δ受体亚型的cDNA鉴定是重要的
由于选择性放射性配体不可用,这阻碍了
开发针对这些亚型的选择性药物。 此外,唯一
研究人类δ阿片受体的方法是通过
使用表达这些受体的重组细胞。 delta的cDNA
受体将在哺乳动物细胞中表达以产生细胞系
具有确定的δ受体亚型。 表达的细胞系
不同的人δ阿片样物质受体亚型将用于
开发特异性放射性配体结合和功能测定,
其他地方提出的新化合物的筛选和表征
这个项目的提案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HENRY I YAMAMURA其他文献
HENRY I YAMAMURA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HENRY I YAMAMURA', 18)}}的其他基金
Functional Domains of the Delta Opioid Receptor
Delta 阿片受体的功能域
- 批准号:
7513579 - 财政年份:2007
- 资助金额:
$ 10.84万 - 项目类别:
MOLECULAR MECHANISM OF ADENYLYL CYCLASE SUPERACTIVATION
腺苷酸环化酶超激活的分子机制
- 批准号:
6556723 - 财政年份:2003
- 资助金额:
$ 10.84万 - 项目类别:
MOLECULAR MECHANISM OF ADENYLYL CYCLASE SUPERACTIVATION
腺苷酸环化酶超激活的分子机制
- 批准号:
6694045 - 财政年份:2003
- 资助金额:
$ 10.84万 - 项目类别:
MOLECULAR MECHANISM OF ADENYLYL CYCLASE SUPERACTIVATION
腺苷酸环化酶超激活的分子机制
- 批准号:
7007630 - 财政年份:2003
- 资助金额:
$ 10.84万 - 项目类别:
MOLECULAR MECHANISM OF ADENYLYL CYCLASE SUPERACTIVATION
腺苷酸环化酶超激活的分子机制
- 批准号:
6838749 - 财政年份:2003
- 资助金额:
$ 10.84万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIOID LIGANDS AND RECEPTORS
阿片类配体和受体的生化特征
- 批准号:
6300719 - 财政年份:2000
- 资助金额:
$ 10.84万 - 项目类别:
BIOCHEMICAL CHARACTERIZATION OF OPIOID LIGANDS AND RECEPTORS
阿片类配体和受体的生化特征
- 批准号:
6104006 - 财政年份:1999
- 资助金额:
$ 10.84万 - 项目类别:
相似海外基金
Establishment and functional analysis of mouse cultured skeletal muscle clone cells lacking insulin 1 and 2
胰岛素1、2缺失小鼠骨骼肌克隆细胞的建立及功能分析
- 批准号:
21K19725 - 财政年份:2021
- 资助金额:
$ 10.84万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Establishment of the iPS cells derived from the paroxysmal nocturnal hemoglobinuria clone cells and its application to a study of bone marrow failure.
源自阵发性睡眠性血红蛋白尿克隆细胞的 iPS 细胞的建立及其在骨髓衰竭研究中的应用。
- 批准号:
25860785 - 财政年份:2013
- 资助金额:
$ 10.84万 - 项目类别:
Grant-in-Aid for Young Scientists (B)